Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biomerica (BMRA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Biomerica (BMRA) over the last 16 years, with Q4 2025 value amounting to 109.17%.

  • Biomerica's EBITDA Margin fell 508600.0% to 109.17% in Q4 2025 from the same period last year, while for Nov 2025 it was 90.11%, marking a year-over-year increase of 105600.0%. This contributed to the annual value of 93.69% for FY2025, which is 165600.0% up from last year.
  • Latest data reveals that Biomerica reported EBITDA Margin of 109.17% as of Q4 2025, which was down 508600.0% from 0.29% recorded in Q3 2025.
  • In the past 5 years, Biomerica's EBITDA Margin ranged from a high of 0.29% in Q3 2025 and a low of 205.07% during Q2 2025
  • Its 5-year average for EBITDA Margin is 98.95%, with a median of 106.6% in 2025.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 1288700bps in 2022, then tumbled by -1484700bps in 2023.
  • Biomerica's EBITDA Margin (Quarter) stood at 24.32% in 2021, then plummeted by -354bps to 110.32% in 2022, then increased by 13bps to 96.17% in 2023, then soared by 39bps to 58.31% in 2024, then tumbled by -87bps to 109.17% in 2025.
  • Its EBITDA Margin was 109.17% in Q4 2025, compared to 0.29% in Q3 2025 and 205.07% in Q2 2025.